NRC draft guidance DG-8070 on patient release after radiopharmaceutical therapy opens for comment

The U.S. Nuclear Regulatory Commission proposes new guidance (DG-8070) for releasing patients after radiopharmaceutical therapy, emphasizing caregiver exposure and keeping dose to others under 5 mSv. Comment by Sept 10.

• The guidance covers unsealed radioactive material and implants, helping providers estimate timing and risks of release, with a focus on caregiver radiation exposure.
• An earlier 2024 draft was dropped due to technical complexity; NRC’s Advisory Committee on the Medical Uses of Isotopes will discuss the proposal Aug 17.
• Current rules allow release if total effective dose to any other individual is unlikely to exceed 5 mSv; new draft provides caregiver-specific dose guidelines.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.